1. Home
  2. ATNM vs GRNQ Comparison

ATNM vs GRNQ Comparison

Compare ATNM & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$0.86

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

Logo Greenpro Capital Corp.

GRNQ

Greenpro Capital Corp.

HOLD

Current Price

$1.25

Market Cap

23.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
GRNQ
Founded
2000
2013
Country
United States
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
31.7M
23.6M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
ATNM
GRNQ
Price
$0.86
$1.25
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
103.0K
5.2K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
14.17
N/A
EPS
N/A
N/A
Revenue
$90,000.00
$3,673,997.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.11
24.55
52 Week Low
$0.88
$1.04
52 Week High
$1.81
$3.18

Technical Indicators

Market Signals
Indicator
ATNM
GRNQ
Relative Strength Index (RSI) 35.93 40.06
Support Level N/A N/A
Resistance Level $1.27 $1.84
Average True Range (ATR) 0.05 0.09
MACD -0.00 -0.00
Stochastic Oscillator 2.53 45.96

Price Performance

Historical Comparison
ATNM
GRNQ

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.

Share on Social Networks: